Professor Zoe Winters

Cyclin dependent Kinase inhibitors (CDKIs) are currently used with endocrine treatments that block ER+ breast cancers In more advanced breast cancers = HER2 positive, CDKIs double the length of progression free survival when combined with (Letrozole). pubmed.ncbi.nlm.nih.gov/41604639/

pubmed.ncbi.nlm.nih.gov/40783288/ Consolidating 10 years of adjuvant (AIT) significantly reduces risks of breast cancer recurrences (both local & distant). Benefits also occur with 5 years of upfront Tamoxifen, followed by 5 years of AIT. Bone health discussion to be had.

Neoadjuvant Deruxtecan or Trastuzumab is an antibody-drug conjugate that optimises breast cancer cell killing in HER positive and HR positive early or high risk breast cancers. The overall aim of achieving a significant pCR was 67% versus 56% after SOC chemotherapy with THP.

Breast cancer surgeons are mindful of reducing or omitting armpit surgery in patients that meet evidence-based criteria. We aim to follow the current randomised trial data, including large published data sets and to offer these options to all eligible women with breast cancer.

Low risk DCIS should not be regarded as “cancer” 8-year risk of a cancer event following a DCIS diagnosis doesn’t exceed 11%, and is comparable to benign atypia We require effective risk stratification tools and shared decision-making bmj.com/content/390/bm…

londonbreasthealth.com/hormone-replac… Modern combination HRT (oestrogen and progesterone) use in women over 55 years is predicted to increase breast cancers risks slightly, equivalent to excess alcohol (more than 10g per day; to result in 1 extra cancer in 100 women)

There is no 10 year overall survival benefit for chest wall radiotherapy after mastectomy and axillary surgery; in the majority of women with intermediate risk breast cancer (clinical stage 1 or 2) emjreviews.com/oncology/news/…

Early detection of the ER+ resistance gene ESR1 at 2 years after endocrine treatment improves outcomes using Camizestran. pubmed.ncbi.nlm.nih.gov/40454637/

This stance is a gamechanger in de-escalating a technique that carries side effects & has quality of life issues. We need to wait & see whether omission of SLNB in early BC remains compatible with varying doses of breast radiotherapy in women at 50 plus. pubmed.ncbi.nlm.nih.gov/40209128/

Reporting individual women's mammogram breast tissue density score; either a C or D (BIRADS A-D), therefore "dense" mandates additional breast screening tests and should be practised throughout the UK. dailymail.co.uk/health/article…

US women must be told breast density after mammogram, says FDA bmj.com/content/386/bm… I wholeheartedly endorse this practice and look forward to this becoming the norm in the UK

News from San Antonio Breast Cancer meeting December 2024 – helping older women avoid axillary surgery safely londonbreasthealth.com/wp-content/upl…

Clinicians need to integrate discussions on genitourinary symptoms in breast cancer survivors, and also clarify referral pathways that formerly link Oncologists and Menopause specialists

Clinicians are increasingly faced with menopause induced issues after breast cancer treatment. A new pilot study called VIBRA, is evaluating the clinical benefits of vaginal prasterone or DHEA in breast cancer survivors, which may be the future.

A breast lump is the most common symptom of breast cancer. What defines a lump? What do you look for? How do you self examine? All perceived lumps, need to be clinically checked to rule out cancer. londonbreasthealth.com/breast-cancer/…

I am humbled and thrilled to be awarded this certificate of excellence by @iwantgreatcare I couldn't do it without the excellent team I work with at each of the hospitals for providing the best possible care for our patients. #cofexcellence2024

youtube.com/live/-hQX2SGlc… via @YouTube Professor Martha Hickey describes how menopause is not one thing for all women in terms of its definition or how it feels - therefore there cannot be one treatment for all. Keep one's views based on emerging knowledge and clinical evidence

We are delighted to support the use of this new anti HER2 drug called Pyrotinib for women with metastatic Stage 4 breast cancer. Pyrotinib effectively blocks all HER2 receptors and doubles disease free survival from 12 to 24 months. Amazing work

Post Menopausal weight gain is a significant risk factor that increases risks of breast cancer by 20-60%, whereas weight loss after menopause is associated with a decreased risk of breast cancer. bmj.com/content/382/bm…